Effect of adjunctive ranitidine for antipsychotic-induced weight gain: A systematic review of randomized placebo-controlled trials

Journal of International Medical Research

Volumn 46, Issue 1, 2018, Pages 22-32

  Gu, Xiao Jing ^a   Chen, Rui ^b   Sun, Chen Hui ^c   Zheng, Wei ^d   Yang, Xin Hu ^d   Wang, Shi Bin ^e   Ungvari, Gabor S ^f,g   Ng, Chee H ^h   Golenkov, Andrei ⁱ   Lok, Grace K I ^e   Li, Lu ^e   Chow, Ines H I ^e   Wang, Fei ^e   Xiang, Yu Tao ^e  

^a The Second Affiliated Hospital of Xinxiang Medical University Henan Mental Hospital   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SHANDONG MENTAL HEALTH CENTER   (China)

^d GUANGZHOU MEDICAL UNIVERSITY   (China)

^e University of Macau   (Macao)

^f UNIVERSITY OF NOTRE DAME   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ CHUVASH STATE UNIVERSITY   (Russian Federation)

Author keywords

Antipsychotics; Meta analysis; Negative symptom; Ranitidine; Schizophrenia; Weight gain

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RANITIDINE; PROTECTIVE AGENT;

ADJUVANT THERAPY; AKATHISIA; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; BODY WEIGHT GAIN; BODY WEIGHT LOSS; COMBINATION DRUG THERAPY; CONSTIPATION; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HUMAN; META ANALYSIS; MONOTHERAPY; MUSCLE RIGIDITY; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; XEROSTOMIA; ADULT; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; PATHOPHYSIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; FEMALE; HUMANS; MALE; PLACEBOS; PROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANITIDINE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 85041427492     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060517716783     Document Type: Review

References (28)

1. Correll CU, Sikich L, Reeves G, et al. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry 2013; 170: 947–952.
2. Maayan L, Vakhrusheva J and Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010; 35: 1520–1530.
3. Zheng W, Li XB, Tang YL, et al. Metformin for weight Gain and metabolic abnormalities associated with antipsychotic treatment: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2015; 35: 499–509.
4. Wu RR, Zhang FY, Gao KM, et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Mol Psychiatry 2016; 21: 1537–1544.
5. Liu Z, Zheng W, Gao S, et al. Metformin for treatment of clozapine-induced weight gain in adult patients with schizophrenia: a meta-analysis. Shanghai Arch Psychiatry 2015; 27: 331–340.
6. Zheng W, Xiang YT, Xiang YQ, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016; 134: 385–398.
7. Zheng W, Zheng YJ, Li XB, et al. Efficacy and safety of adjunctive aripiprazole in schizophrenia: meta-analysis of randomized controlled trials. J Clin Psychopharmacol 2016; 36: 628–636.
8. Curtis J, Watkins A, Rosenbaum S, et al. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry 2016; 10: 267–276.
9. Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40: 1385–1403.
10. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 297–302.
11. Choi YJ. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal 2015; 2015: 970730.
12. Baptista T, Kin NM, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35: 205–219.
13. Mehta VS and Ram D. Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study. Early Interv Psychiatry 2014; 10: 522–527.
14. Ranjbar F, Ghanepour A, Sadeghi-Bazargani H, et al. The effect of ranitidine on olanzapine-induced weight gain. Biomed Res Int 2013; 2013: 639391.
15. Sun J, Xi XD, Li Y, et al. The effect of ranitidine on olanzapine-induced weight gain and metabolic dysfunction [In Chinese]. Chinese Journal of Nervous and Mental Diseases 2007; 33: 560–562.
16. Liang MJ. Effects of ranitidine on the glucose and lipid metabolism level and body mass of patients with olanzapine in treatment of schizophrenia [In Chinese]. Evaluation and Analysis of Drug-use in Hospitals of China 2016; 16: 433–436.
17. Kay SR, Fiszbein A and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276.
18. Overall JE and Gorham DR. The brief psychiatric rating-scale. Psychol Rep 1962; 10: 799–812.
19. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264–269, W264.
20. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152–163.
21. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
22. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
23. Higgins J and Higgins J. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: John Wiley & Sons, 2008.
24. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.
25. Lopez-Mato A, Rovner J, Illa G, et al. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]. Vertex 2003; 14: 85–96. [in Spanish, English Abstract].
26. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
27. Doi T, Sakata T, Yoshimatsu H, et al. Hypothalamic neuronal histamine regulates feeding circadian rhythm in rats. Brain Res 1994; 641: 311–318.
28. Reynolds GP and Kirk SL. Metabolic side effects of antipsychotic drug treatment– pharmacological mechanisms. Pharmacol Ther 2010; 125: 169–179.